(Reuters) -Gilead Sciences said on Friday its breast cancer drug Trodelvy did not significantly lower the risk of disease progression in patients when used as a first-line treatment, failing to meet the main goal of a late-stage study.
Gilead said an early trend for extending overall survival, a key measure of treatment efficacy, was observed favoring patients treated with Trodelvy, compared to chemotherapy.
The data for overall survival, however, was not mature at the time of the primary analysis, the company said, adding that the study will continue to assess this secondary goal.
Trodelvy was being tested in patients with HR+/HER2-negative metastatic breast cancer, the most common subtype of the cancer, as a first-line treatment following hormone therapy.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Shailesh Kuber)
Comments